DESCOVY® tablets

DESCOVY® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) is a dual-NRTI backbone, which is an element of a complete HIV-1 regimen.1,2

DESCOVY is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients weighing at least 35 kg.

  • View full Prescribing Information for DESCOVY®, including BOXED WARNING.

Important Safety Information

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

Warnings and precautions

Adverse reactions

Drug interactions

Dosage and administration

Pregnancy and lactation

Indication

DESCOVY® is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients weighing at least 35 kg.

FTC, emtricitabine; NRTI, nucleoside reverse transcriptase inhibitor; TAF, tenofovir alafenamide.
References:

  1. DESCOVY.Package insert. Gilead Sciences, Inc.; 2021.
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated December 18, 2019. Accessed March 10, 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf
Back to top